title: Investigational antimicrobial agents of 2013.
abstract: New antimicrobial agents are always needed to counteract the resistant pathogens that continue to be selected by current therapeutic regimens. This review provides a survey of known antimicrobial agents that were currently in clinical development in the fall of 2012 and spring of 2013. Data were collected from published literature primarily from 2010 to 2012, meeting abstracts (2011 to 2012), government websites, and company websites when appropriate. Compared to what was reported in previous surveys, a surprising number of new agents are currently in company pipelines, particularly in phase 3 clinical development. Familiar antibacterial classes of the quinolones, tetracyclines, oxazolidinones, glycopeptides, and cephalosporins are represented by entities with enhanced antimicrobial or pharmacological properties. More importantly, compounds of novel chemical structures targeting bacterial pathways not previously exploited are under development. Some of the most promising compounds include novel β-lactamase inhibitor combinations that target many multidrug-resistant Gram-negative bacteria, a critical medical need. Although new antimicrobial agents will continue to be needed to address increasing antibiotic resistance, there are novel agents in development to tackle at least some of the more worrisome pathogens in the current nosocomial setting.
authors.affiliation: Achillion Pharmaceuticals, New Haven, Connecticut, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Pucci
authors.forename: Karen
authors.initials: K
authors.lastname: Bush
mesh_terms: D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D003015:Clostridium Infections / Q000188:drug therapy; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006306:Health Surveys; D006801:Humans; D018716:Molecular Mimicry; D011500:Protein Synthesis Inhibitors / Q000737:chemistry / Q000494:pharmacology; D059003:Topoisomerase Inhibitors / Q000737:chemistry / Q000494:pharmacology; D014376:Tuberculosis / Q000188:drug therapy; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams / Q000737:chemistry / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D001426:Bacterial Proteins; D004338:Drug Combinations; D015507:Drugs, Investigational; D011500:Protein Synthesis Inhibitors; D059003:Topoisomerase Inhibitors; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams